The benefit in survival was confirmed in MIRASOL, a phase 3 global, confirmatory, open-label, randomized, controlled trial comparing mirvetuximab soravtansine with the investigators’ choice of chemotherapy in platinum-resistant, high-grade serous OC with high FRα tumor expression (≥75% of cells with ≥2+ staining intensity) [2]. This evidence concerns the gene FOLR1 and neoplasm.